Review Article

**JOURNAL OF DRUG REACTIONS**
An international online peer reviewed, open access Journal
Content available at www.cognixpress.in Online ISSN: 3139-4132

# REGULATORY FRAME WORK IN DRUG SAFETY AND PHARMACOVIGILANCE

**SUGALI ARUNA*,A.JYOSTHNA, P.MOHAN VIKAS, CHANDU BABU RAO**

*Priyadarshini Institute of Pharmaceutical Education and Research, 5th Mile, Pulladigunta, Guntur-522017, Andhra Pradesh, India.*

***Corresponding Author**
Sugali Aruna

Article History: 14.03.2026 Received: 02.04.2026 Revised: Accepted: 06.06.2026

**ABSTRACT**
Pharmacovigilance is a fundamental component of modern healthcare systems dedicated to thedetection, assessment, monitoring, and prevention of adverse drug reactions (ADRs) and other drug-related problems. With the increasing complexity of therapeutics, biologics, vaccines, and personalized medicine, robust pharmacovigilance systems are essential to ensure patient safety throughout the lifecycle of medicinal products. The evolution of pharmacovigilance was significantly influenced by historical drug-related tragedies, leading to the establishment of global regulatory frameworks. Today, pharmacovigilance integrates spontaneous reporting systems, post-marketing surveillance, electronic health records, real-world evidence, artificial intelligence, and signal detection methodologies. Despite substantial progress, challenges such as underreporting, regulatory inconsistencies, and limited awareness persist, particularly in developing countries. Future perspectives emphasize proactive risk management, precision medicine, global collaboration, and digital transformation. This review discusses the history, importance, regulatory framework, methodologies, challenges, and future directions of pharmacovigilance in ensuring drug safety worldwide.

***Keywords:*** *Drug Safety, Pharmacovigilance, Adverse Drug Reactions, Signal Detection, Risk Management, Regulatory Framework, Real-World Evidence.*



## 1. INTRODUCTION

Pharmacovigilance is defined by the World Health Organization as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. It plays a crucial role in safeguarding public health by monitoring medicines throughout their lifecycle.

Before marketing approval, drugs are tested in controlled clinical trials involving limited populations. However, rare, delayed, or population-specific adverse drug reactions (ADRs) may not be detected during these trials. Therefore, post-marketing surveillance becomes essential.

Globally, ADRs are a significant cause of morbidity and mortality. Reports estimate thousands of deaths annually due to drug-related complications [1]. This underscores the importance of systematic monitoring systems such as the Programme for International Drug Monitoring coordinated by the Uppsala Monitoring Centre.

India joined the WHO monitoring programme in 1998 and later established the Pharmacovigilance Programme of India (PvPI) to strengthen national ADR monitoring.

## 2.HISTORICAL BACKGROUND OF PHARMACOVIGILANCE

Pharmacovigilance emerged primarily due to major drug-related disasters.

The Sulphanilamide Tragedy (1937)

The use of diethylene glycol as a solvent in sulphanilamide resulted in over 100 deaths in the United States. This led to the strengthening of drug safety laws.

The Thalidomide Disaster (1957–1961)

The thalidomide tragedy caused severe birth defects when used by pregnant women. This catastrophe revolutionized drug regulation worldwide and led to stricter safety requirements.

In response, the WHO established the Programme for International Drug Monitoring (1968) coordinated by the Uppsala Monitoring Centre.[2]Regulatory Milestones.

1962: Kefauver Harris Amendment mandated proof of safety and efficacy before approval.
1995: Establishment of the European Medicines Agency.
Strengthening of the U.S. Food and Drug Administration post-marketing surveillance.
These reforms laid the foundation for structured pharmacovigilance systems globally.

## 3. IMPORTANCE AND SCOPE OF PHARMACOVIGILANCE

Throughout the product lifecycle, pharmacovigilance is crucial and essential for ensuring safety. Post marketing surveillance and clinical trial safety are both vital components of this process. Pharmacovigilance is not advanced in India, and limited information is available on the topic. In contrast, the western countries have made substantial progress. Reporting pharmacovigilance significantly affects a product's life cycle by ensuring its significance is understood [3]. Best practices for pharmacovigilance can be incorporated into the procedures and processes to assure regulatory compliance, improve clinical trial safety, and monitor products once they are on the market, making it possible for these activities to be carried out effectively.
Pharmacovigilance ensures that:Rare ADRs are detected.
Drug safety in special populations (pregnant women, pediatrics, geriatrics) is evaluated.
Benefit-risk balance is continuously assessed.Regulatory decisions are evidence-baed.
At licensing, drugs are typically tested in fewer than 5,000 individuals, making post-marketing monitoring essential
Core Activities:Spontaneous, reporting Case series, developmentSignal detection, Data mining, Riskmanagement, Pharmacovigilance also builds public confidence in healthcare systems by promoting transparency.

## 4. AIM AND OBJECTIVES

Ameliorate the quality of care as well as protection for any use of tradition medicines but all healthcare but also direct ament treatment options. also For reason, thus, it's vital the said innovative but pharmacologically nonetheless developing remedies have been watched nearly for his or her safety inadequately truesituation. redundant data is generally largely needed about it using through specific populations, prominently youthful kiddies, women who are pregnant as well as the aged, and also about the safety and efficacity after all patient application, especially in confluence with some other drugs [4]. The primary aims include:Enhancing patient safety.Early detection of new ADR signals.Risk-benefit assessment of medicines.Supporting regulatory decision-making.Promoting rational drug use.Educating healthcare professionals and the public.

## 5. ADVANTAGES AND DISADVANTAGES

5.1 Advantages

- Improves public health safety.Supports regulatory decisions.
- Identifies rare and serious ADRs.Enhances trust in pharmaceutical products.
- Utilizes AI and big data for rapid signal detection.

5.2 Disadvantages

- Underreporting (only 6–10% of ADRs reported).
- Incomplete case information.Misclassification or miscoding.
- Limited awareness among healthcare professionals.

## 6. PARTNERS IN PHARMACOVIGILANCE

A fancy but rather regarded as essential remains among both vast varies yeah collaborators with in exercise like pharmacovigilance going to cover. saved cooperative trouble but rather responsibility also essential unborn problems throughout forestallment and control are now to be considered in order versus establish as well as blossom. current , governance manufacturing, clinic but also faculty [5]. Trying to report adverse medicine events covering the story adverse events Reporting adverse goods covering the story adverse response (are) covering the story is most generally associated of pharmaceutical care as well as ingests numerous like reserves of administration public realities but rather civil medicine police as well as pharmacovigilance department of the company throughout pharma organisational
Pharmacovigilance is a shared responsibility involving

- Healthcare Professionals Physicians, Nurses, Pharmacists,
- Patient reporting systems such as the Yellow Card Scheme enhance safety awareness.
- Pharmaceutical Industry Responsible for post-marketing surveillance and risk management.
- Regulatory AuthoritiesU.S. Food and Drug AdministrationEuropean Medicines AgencyCentral Drugs Standard Control Organization
- Global Organizations World Health Organization uppsala Monitoring Centre

## 7. METHODS OF PHARMACOVIGILANCE

Pharmacovigilance styles that can be employed in specific circumstances is grounded upon de the original situation, experience, moxie, and coffers available to achieve these objects active surveillance This system depends on active follow- up of cases after treatment, and all adverse responses are detected either by asking cases directly or by screening the case records. Cohort event monitoring Cohort studies are studies that identify subsets of a defined population and follow them over time, looking for differences in their outgrowth. Cohort studies generally are used to compare exposed cases to unexposed cases or one exposure to another.cohort

studies have numerous advantages [6]. They're the stylish way to ascertain both the prevalence and natural history of complaint, temporal sequence between cause and outgrowth is generally clear, useful in disquisition of multiple issues that might arise after a single exposure, useful in the study of rare exposure.

- Passive SurveillanceSpontaneous reporting systems
- Active SurveillanceCohort Event Monitoring (CEM) Registries
- Observational Studies Cohort studiesCase-control studies
- Data Mining Techniques, Signal detection algorithms, Disproportionality analysis

## 8. ROLE IN DRUG SAFETY

Pharmacovigilance and medicine safety are critical disciplines to give assurance of the safe and effective use of drugs during their lifecycle. These practices are designed to descry, estimate, understand, and help adverse medicine responses (ADRs) and other medicine-related issues, therefore. securing public health and enhancing patient issues.

Safety problems through conventional medical practising, if any of these enterprises feel to be applicable of between new nonsupervisory response or indeed to issues the said arise with in public sphere. From the other, nonsupervisory bodies ought to fete this same specialty but also prominent part and it medicine safety games throughout guaranteeing the uninterrupted security after all remedial goods. The part of pharmacovigilance in observing the pitfalls associated with medicines has been extensively accepted.

Discovery of adverse medicine response (ADRs) PV systems descry and track ADRs by robotic reporting, clinical trials, post-marketing surveillance, and electronic health records. Risk Assessment and Management Collected safety data are estimated to determine pitfalls associated with medicines. Effective threat minimization strategies are also formulated and enforced. - Decision-Making Pharmacovigilance assists nonsupervisory agencies (similar as the FDA, EMA, and CDSCO) to make substantiation- grounded opinions on medicine blessings, labelling changes, restrictions, or recessions. 4. Case and Healthcare professional Education PV raises cases' and prescribers' of medicine safety and the need for reporting adverse events.

Pharmacovigilance contributes by: Detecting ADRs. Managing risks.

Supporting regulatory action. Educating healthcare professionals. Monitoring post-marketing safety.

Facilitating global data exchange.

## 9. REGULATORY FRAMEWORK IN PHARMACOVIGILANCE

In the U.S., the FDA observers medicine safety through programs like, where healthcare professionals and the public can report adverse good, also the European Medicines Agency (EMA) oversees pharmacovigilance in Europe through its system, icing that any arising safety issues are addressed fleetly [18-19]. International Guidelines( ICH, CIOMS) International guidelines help harmonize medicine safety practices across countries. Formalized protocols for the evaluation and monitoring of medicine safety are handed by the International Council for Harmonisation of Technical Conditions for medicinals for mortal Use( ICH). These protocols include Good Pharmacovigilance Practices( GVP), also, the Council for International Associations of Medical lores( CIOMS) develops global guidelines on medicine safety, threat operation, and reason assessment to grease cooperation between countries in addressing ADRs [7, 20].

International Guidelines

The International Council for Harmonisation provides E2E pharmacovigilance guidelines.

The Council for International Organizations of Medical Sciences develops global risk management recommendations.

National Regulatory SystemsIndia, Central Drugs Standard Control Organization, Pharmacovigilance Programme of India (PvPI), United States, U.S. Food and Drug Administration, Europe European Medicines Agency

## 10.EARLY DETECTION OF ADVERSE DRUG REACTIONS

Biomarkers can help identify individualities who are more susceptible to certain adverse goods, therefore allowing for individualized drug approaches to minimize medicine toxin( World Health Organization, 2020).[8] likewise, large- scale experimental studies and databases, similar as the WHO's Vlgibase, give global ADR reporting and discovery, easing the identification of rare or unanticipated ADRs across different populations. Adverse medicine responses( ADRs) pose significant pitfalls to public health, performing in millions of severe cases and thousands of deaths every time. Conventional discovery with the help ofpost-marketing reports is less effective for recently approved drugs because of limited information. To overcome this, a new frame of marker propagation was designed that combines medicine chemical structure parallels with FAERS data. This system improves the perfection of ADR discovery, particularly for medicines

Early detection prevents serious harm.

Tools include:Electronic Health Records (EHRs),Clinical Decision Support Systems (CDSS)

Biomarkers,Real-world evidence databases,WHO's global database (VigiBase)
Artificial intelligence enhances signal detection by analyzing large datasets.

## 11.CHALLENGES AND LIMITATIONS

Challenges in reason assessment Regulatory and legal factors oppressively stymie the effective operation of pharmacovigilance systems, especially in low- and middle-income countries( LMICs). The most serious among these are the lack of general laws calling adverse medicine response( ADR) reporting, weak enforcement of being laws, inadequate legal accreditation on assiduity actors, and shy legal protection for healthcare professionals reporting ADRs [9]. These gaps lead to fractured systems, underreporting, and poor data integration.
Croakers feel that ultimate of the time they need to report only if the adverse events has casual relationship with the products. In our nation, in view of low croaker-to- case rate, ultimate of the events are n't reported because of lack of time, low provocation, ignorance and languor. In malice of having trained medical professional in our nation, sometimes croakers are reticent to report because they're hysterical of being sued and believes reporting would work against them. Lack of training for undergraduates on pharmacovigilance.
Underreporting of ADRsLack of awareness
Legal and regulatory barriersLimited resources in low- and middle-income countries,
Data interoperability issue
Fear of legal consequences among reporters

## 12. FUTURE DIRECTIONS IN PHARMACOVIGILANCE

The challenges to manage medicine safety efficiently and to cleave to nonsupervisory conditions produce the strong print that wide relinquishment of pharmacovigilance is ineluctable [10]. As an instrument of reform, pharmacovigilance has attributes that insure its attractiveness to numerous groups in a politically and economically disunited health care system that's floundering with putatively invincible problems of cost and quality and post marketing clinical studies as well. Regulatory bodies similar as FDA and European Medicines Agency( EMEA) are enhancing safety regulations, thus boosting the relinquishment rates of pharmacovigilance systems by biopharmaceutical enterprises.16 still, the apparent certainty of pharmacovigilance relinquishment needs to be co 12.1. Precision Medicine and Pharmacovigilance Advancements in Technology The future of pharmacovigilance is being shaped by rapid-fire advancements in technology, particularly through the integration of artificial intelligence( AI) and machine literacy( ML) in data analysis.

- Artificial Intelligence and Machine Learning,
- AI improves signal detection accuracy and speed.
- Precision MedicinePersonalized risk prediction using genomics.
- Big Data and Real-World Evidence,
- Use of insurance claims, EHRs, wearable data.
- Global CollaborationInternational data sharing strengthens safety monitoring.

## 13. FUTURE PROSPECTIVE

Big Data and Real World substantiation Classical medicine safety surveillance systems similar as FAERS and Eudra Vigilance are agonized by issues of underreporting and signal detention. These are overcome by exercising Electronic Health Records( EHRs) and medical literature as ancillary tools. EHRs give timely, large- scale clinical data that aids in early discovery and analysis of medicine adverse events. Medical literature with peer- reviewed information, is uprooted by styles similar as natural language processing to identify medicine safety signals. In combination, these styles enhance the efficacity, effectiveness, and responsiveness of pharmacovigilance. Modern pharmacovigilance integrates:Big data analyticsNatural Language Processing (NLP) Real-world evidence (RWE). Digital reporting platforms, Patient-centric approaches Regulatory agencies increasingly rely on RWE for decision-making and label updates. Sophisticated analytics similar as machine literacy and NLP help in relating safety signals from big data, while nonsupervisory agencies work RWE to support well-informed decision- making regarding medicine safety and labelling.

## 14.CONCLUSION

Pharmacovigilance is an indispensable pillar of public health protection. It ensures the continuous evaluation of the safety and effectiveness of medicinal products from clinical trials to post-marketing phases. Historical tragedies have shaped modern regulatory frameworks, leading to global cooperation and standardized monitoring systems.
Although significant progress has been made, challenges such as underreporting and regulatory disparities remain. Future advancements in artificial intelligence, precision medicine, and global data sharing will transform pharmacovigilance into a more proactive and predictive discipline. Strengthening education, regulatory harmonization, and patient participation will ensure safer use of medicines worldwide.

## 15.AUTHOR CONTRIBUTIONS

All authors are contributed equally.

**16. FINANCIAL SUPPORT**
None

**17. DECLARATION COMPETING INTEREST**
The authors have no conflicts of interest to declare.

**18. ACKNOWLEDGEMENT**
None

**19. REFERENCES**

1. Biswas P, Biswas AK. Setting standards for proactive pharmacovigilance in India: the way forward. Indian J Pharmacol. 2007;39(3):124-128. doi:10.4103/0253-7613.3343.
2. Kumanan R, Sudha S, Vijayashre P, Charumath S, Gowridevi KC, Mahesh M. Imperative approach on pharmacovigilance in Indian systems of medicines. Int J Pharma Sci Res. 2010;1(9):378-390.
3. Rodieux F, Piguet V, Desmeules J, Samer CF. Safety issues of pharmacological acute pain treatment in children. Clin Pharmacol Ther. 2019;105(5):1130-1138. doi:10.1002/cpt.1358.
4. Gangarosa EJ, Galazka AM, Wolfe CR, Phillips LM, Miller E, Chen RT, et al. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet. 1998;351(9099):356-361. doi:10.1016/S0140-6736(97)04334-1.
5. Bloem LT, van der Elst ME, Klungel OH. Principles of pharmacovigilance and drug regulation. In: Klungel OH, editor. Principles and Practice of Pharmacovigilance and Drug Safety. Cham: Springer International Publishing; 2024. p. 135-161.
6. Kao J, Van de Wiele VL, Beall RF, Sarpatwari A. Impact of risk evaluation and mitigation strategies on generic approvals of US pharmaceutical products. Health Aff (Millwood). 2025;44(10):1285-1290.
7. Saravanan D, Muthudoss P, Khullar P, Venis AR. Quantitative microscopy: particle size/shape characterization, addressing common errors using the analytics continuum approach. J Pharm Sci. 2021;110(2):833-849.
8. Council for International Organizations of Medical Sciences. Practical approaches to risk minimisation for medicinal products: report of CIOMS Working Group IX. Geneva: CIOMS; 2014.
9. Esslinger S, Quinn L, Sampat S, Otero-Lobato M, Noël W, Geldhof A, Herijgers N, Reeder SJ. Risk management plans: reassessment of safety concerns based on Good Pharmacovigilance Practices Module V (Revision 2)-a company experience. J Pharm Health Care Sci. 2022;8(1):14. doi:10.1186/s40780-022-00244-7.
10. Castellana E, Budau PM, Chiappetta MR. Pharmacovigilance: overview of Italian and European regulations, tools, and perspectives. Int J Risk Saf Med. 2025;36(4):147-155.
11. Nama S, Chandu BR, Awen BZ, Khagga M. Development and validation of a new RP-HPLC method for the determination of aprepitant in solid dosage forms. Trop J Pharm Res. 2011;10(4):489-495.
12. Gindi S, Methra T, Chandu BR, Boyina R, Dasari V. Antiurolithiatic and in vitro antioxidant activity of leaves of *Ageratum conyzoides* in rats. World J Pharm Pharm Sci. 2013;2:636-649.
13. Rao C. Evaluation of antiulcer activity of *Picrasma quassioides* Bennett aqueous extract in rodents. Vedic Res Int Phytomedicine. 2013.
14. Degapati RT. Novel approaches in transdermal drug delivery system. J Multidiscip Res. 2025:20-25.
15. Nanjwade BK, Bechra HM, Derkar GK, Manvi FV, Nanjwade VK. Dendrimers: emerging polymers for drug-delivery systems. Eur J Pharm Sci. 2009;38(3):185-196. doi:10.1016/j.ejps.2009.07.008.
16. Rani CU, Sumalatha G, Rao CB, Varalakshmi TN. Alzheimer's disease-pharmacotherapeutic interventions. Int J Pharm Chem Sci. 2013;2(2).
17. Bethapudi V, Pasam NA, Velchuri S, Chandu BR. Dendrimers: emerging polymers for drug delivery and its future prospects. Res J Pharm Biol Chem Sci. 2012;3(2):735-747.